These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29986213)

  • 1. The use of small-molecule structures to complement protein-ligand crystal structures in drug discovery.
    Groom CR; Cole JC
    Acta Crystallogr D Struct Biol; 2017 Mar; 73(Pt 3):240-245. PubMed ID: 28291759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent fragment-based drug discovery for target tractability.
    McCarthy WJ; van der Zouwen AJ; Bush JT; Rittinger K
    Curr Opin Struct Biol; 2024 Jun; 86():102809. PubMed ID: 38554479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular glues for protein-protein interactions: Progressing toward a new dream.
    Konstantinidou M; Arkin MR
    Cell Chem Biol; 2024 Jun; 31(6):1064-1088. PubMed ID: 38701786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated Absolute Binding Free Energy Calculation Workflow for Drug Discovery.
    Ries B; Alibay I; Anand NM; Biggin PC; Magarkar A
    J Chem Inf Model; 2024 Jul; 64(14):5357-5364. PubMed ID: 38952038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate Characterization of Binding Kinetics and Allosteric Mechanisms for the HSP90 Chaperone Inhibitors Using AI-Augmented Integrative Biophysical Studies.
    Xu C; Zhang X; Zhao L; Verkhivker GM; Bai F
    JACS Au; 2024 Apr; 4(4):1632-1645. PubMed ID: 38665669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering.
    Shevyrev DV; Tereshchenko VP; Sennikov SV
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Kinetic Relationship Studies for the Development of Long Residence Time LpxC Inhibitors.
    Basak S; Li Y; Tao S; Daryaee F; Merino J; Gu C; Delker SL; Phan JN; Edwards TE; Walker SG; Tonge PJ
    J Med Chem; 2022 Sep; 65(17):11854-11875. PubMed ID: 36037447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of Multidirectional Pathways for Ligand Release from the Receptor: A New Approach Based on Differential Evolution.
    Nguyen HL; Thai NQ; Li MS
    J Chem Theory Comput; 2022 Jun; 18(6):3860-3872. PubMed ID: 35512104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritonavir and xk263 Binding-Unbinding with HIV-1 Protease: Pathways, Energy and Comparison.
    Sun J; Raymundo MAV; Chang CA
    Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A structure-kinetic relationship study using matched molecular pair analysis.
    Schuetz DA; Richter L; Martini R; Ecker GF
    RSC Med Chem; 2020 Sep; 11(11):1285-1294. PubMed ID: 34085042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic Heterogeneity of Cancer Cell Fractional Killing.
    Inde Z; Forcina GC; Denton K; Dixon SJ
    Cell Rep; 2020 Jul; 32(1):107845. PubMed ID: 32640215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy.
    Wang G; Ji Y; Li X; Wang Q; Gong H; Wang B; Liu Y; Pan Y
    Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31527517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics.
    Daryaee F; Tonge PJ
    Curr Opin Chem Biol; 2019 Jun; 50():120-127. PubMed ID: 31030171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.
    Lu H; Iuliano JN; Tonge PJ
    Curr Opin Chem Biol; 2018 Jun; 44():101-109. PubMed ID: 29986213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches for computing ligand-receptor binding kinetics.
    Bruce NJ; Ganotra GK; Kokh DB; Sadiq SK; Wade RC
    Curr Opin Struct Biol; 2018 Apr; 49():1-10. PubMed ID: 29132080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying thermodynamic profiling in lead finding and optimization.
    Klebe G
    Nat Rev Drug Discov; 2015 Feb; 14(2):95-110. PubMed ID: 25614222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational modeling approaches to quantitative structure-binding kinetics relationships in drug discovery.
    De Benedetti PG; Fanelli F
    Drug Discov Today; 2018 Jul; 23(7):1396-1406. PubMed ID: 29574212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery.
    Williams G; Ferenczy GG; Ulander J; Keserű GM
    Drug Discov Today; 2017 Apr; 22(4):681-689. PubMed ID: 27916639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Approaches to GPCR Ligand Screening for Drug Discovery.
    Kumari P; Ghosh E; Shukla AK
    Trends Mol Med; 2015 Nov; 21(11):687-701. PubMed ID: 26481827
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.